does tirzepatide reduce alcohol cravings Semaglutide and consumption in individuals with obesity Semaglutide and Tirzepatide reduce alcohol

This study evaluated semaglutides effects on body weight, health status, and mood in obese HF patients over one year

" " ,

Know Zoloft side effects, Zoloft dosage, and more.

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium.“Psoriatic arthritis seems to have a special place for increased risk for obesity,&rdquo

Study Snapshot Design: Randomized, double-blind, placebo-controlled trial Duration: 26 weeks Population: Treatment-seeking adults with AUD + obesity Completers: 88 participants Intervention: Once-weekly semaglutide + behavioral therapy Funding: Novo Nordisk Foundation Key Findings (Simplified) Heavy drinking days significantly reduced ~41% reduction with semaglutide vs ~26% placebo Treatment effect difference: ~13.7% improvement vs placebo Absolute reduction: ~12 fewer heavy drinking days/month (vs ~8 days in placebo) Alcohol-Related Outcomes Total alcohol intake Frequency of binge/heavy drinking episodes Alcohol craving (supported by prior trials) Biomarker-confirmed reductions in alcohol exposure Metabolic & Somatic Benefits Significant weight loss Improved blood pressure & cardiometabolic profile Reinforces dual benefit: metabolic + behavioral modulation Mechanistic Insight (Emerging) GLP-1 receptor agonists may: Modulate reward pathways Reduce dopamine-driven craving signals Decrease cue-induced alcohol seeking behavior Important Limitations Small sample size (n=88 completers) Conducted in motivated, treatment-seeking population Combined with cognitive behavioral therapy (not drug-only effect) No long-term post-treatment follow-up Why This Matters AUD remains under-treated globally Current pharmacotherapies have limited uptake & modest efficacy Semaglutide introduces a novel, biologically plausible pathway Potential shift toward metabo-psychiatric therapeutics Clinical Takeaway This is not just a weight-loss drug anymore It may represent a new frontier in addiction medicine But: Larger, real-world trials are essential before routine clinical adoption